Empagliflozin Reduces High Glucose-Induced Cardiomyopathy in HiPSC-Derived Cardiomyocytes : Glucose-induced Lipotoxicity in HiPSC-Derived Cardiomyocytes

Overview

Journal Stem Cell Rev Rep

Publisher Springer

Date 2025 Jan 22

PMID 39841369

Authors

Hsiu-Hui Tsai

Fu-Chih Hsiao

Alice L Yu

Jyuhn-Huarng Juang

John Yu

Pao-Hsien Chu

Affiliations

Soon will be listed here.

Abstract

Human-induced pluripotent stem cell (hiPSC) technology has been applied in pathogenesis studies, drug screening, tissue engineering, and stem cell therapy, and patient-specific hiPSC-derived cardiomyocytes (hiPSC-CMs) have shown promise in disease modeling, including diabetic cardiomyopathy. High glucose (HG) treatment induces lipotoxicity in hiPSC-CMs, as evidenced by changes in cell size, beating rate, calcium handling, and lipid accumulation. Empagliflozin, an SGLT2 inhibitor, effectively mitigates the hypertrophic changes, abnormal calcium handling, and contractility impairment induced by HG. Glucose concentration influences SGLT2 expression in cardiomyocytes, highlighting its potential role in diabetic cardiomyopathy. These findings support the potential utility of hiPSC-CMs in studying diabetic cardiomyopathy and the efficacy of empagliflozin in ameliorating HG-induced cardiomyocyte dysfunction. Such research may advance developments in precision medicine and therapeutic interventions for patients with diabetic cardiomyopathy.

References

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

McMurray J, Solomon S, Inzucchi S, Kober L, Kosiborod M, Martinez F . Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381(21):1995-2008. DOI: 10.1056/NEJMoa1911303. View

Packer M, Anker S, Butler J, Filippatos G, Pocock S, Carson P . Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15):1413-1424. DOI: 10.1056/NEJMoa2022190. View

Anker S, Butler J, Filippatos G, Ferreira J, Bocchi E, Bohm M . Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021; 385(16):1451-1461. DOI: 10.1056/NEJMoa2107038. View

Solomon S, McMurray J, Claggett B, de Boer R, DeMets D, Hernandez A . Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022; 387(12):1089-1098. DOI: 10.1056/NEJMoa2206286. View

Jhund P, Kondo T, Butt J, Docherty K, Claggett B, Desai A . Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022; 28(9):1956-1964. PMC: 9499855. DOI: 10.1038/s41591-022-01971-4. View

Butler J, Packer M, Filippatos G, Ferreira J, Zeller C, Schnee J . Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2021; 43(5):416-426. PMC: 8825259. DOI: 10.1093/eurheartj/ehab798. View

10.

Hsiao F, Lin C, Tung Y, Chang P, McMurray J, Chu P . Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study. Int J Cardiol. 2021; 330:91-97. DOI: 10.1016/j.ijcard.2021.02.035. View

11.

Cowie M, Fisher M . SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020; 17(12):761-772. DOI: 10.1038/s41569-020-0406-8. View

12.

Marfella R, Scisciola L, DOnofrio N, Maiello C, Trotta M, Sardu C . Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. Pharmacol Res. 2022; 184:106448. DOI: 10.1016/j.phrs.2022.106448. View

13.

Uthman L, Baartscheer A, Schumacher C, Fiolet J, Kuschma M, Hollmann M . Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients. Front Physiol. 2018; 9:1575. PMC: 6259641. DOI: 10.3389/fphys.2018.01575. View

14.

Chen S, Coronel R, Hollmann M, Weber N, Zuurbier C . Direct cardiac effects of SGLT2 inhibitors. Cardiovasc Diabetol. 2022; 21(1):45. PMC: 8933888. DOI: 10.1186/s12933-022-01480-1. View

15.

Lopaschuk G, Verma S . Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020; 5(6):632-644. PMC: 7315190. DOI: 10.1016/j.jacbts.2020.02.004. View

16.

Kuo M, Tsai H, Wang S, Chen Y, Yu A, Yu J . Yulink, predicted from evolutionary analysis, is involved in cardiac function. J Biomed Sci. 2021; 28(1):7. PMC: 7798328. DOI: 10.1186/s12929-020-00701-7. View

17.

Guo H, Yu X, Liu Y, Paik D, Justesen J, Chandy M . SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common alcohol flushing variant. Sci Transl Med. 2023; 15(680):eabp9952. PMC: 10297796. DOI: 10.1126/scitranslmed.abp9952. View

18.

Tiburcy M, Hudson J, Balfanz P, Schlick S, Meyer T, Chang Liao M . Defined Engineered Human Myocardium With Advanced Maturation for Applications in Heart Failure Modeling and Repair. Circulation. 2017; 135(19):1832-1847. PMC: 5501412. DOI: 10.1161/CIRCULATIONAHA.116.024145. View

19.

Zhang J, Zhao S, Tu C, Pang P, Zhang M, Wu J . Protocol to measure contraction, calcium, and action potential in human-induced pluripotent stem cell-derived cardiomyocytes. STAR Protoc. 2021; 2(4):100859. PMC: 8551496. DOI: 10.1016/j.xpro.2021.100859. View

20.

Karakikes I, Ameen M, Termglinchan V, Wu J . Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes. Circ Res. 2015; 117(1):80-8. PMC: 4546707. DOI: 10.1161/CIRCRESAHA.117.305365. View